Albuterol Spiromax®

DRUG3 trials

Sponsors

Teva Branded Pharmaceutical Products R&D, Inc.

Conditions

AsthmaChronic Obstructive Pulmonary Disease (COPD)

Phase 1

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

CompletedNCT01844401

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2013-04-30End: 2013-10-31Updated: 2013-11-14

Phase 2

A Dose-ranging Study to Evaluate Albuterol and Hydrofluoroalkane in Subjects Ages 12 and Older With Persistent Asthma

CompletedNCT01058863

Teva Branded Pharmaceutical Products R&D, Inc.Asthma

Start: 2010-02-28End: 2010-06-30Updated: 2021-11-09

Phase 3

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

CompletedNCT01857323

Teva Branded Pharmaceutical Products R&D, Inc.Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Start: 2013-05-31End: 2013-09-30Updated: 2015-06-08

Related Papers

Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter

Allergy and Asthma Proceedings2016-02-0111 citations